The embodiments described herein may relate to methods and systems for adjusting insulin delivery. Some methods and systems may be configured to adjust insulin delivery to personalize automated insulin delivery for a person with diabetes. Such personalization may include adjusting user specific dosage parameters in response to one or more back-filled time segments associated with a diurnal time block.

A method of administering insulin includes receiving blood glucose measurements of a patient at a data processing device from a glucometer. Each blood glucose measurement is separated by a time interval and includes a blood glucose time associated with a time of measuring the blood glucose measurement. The method also includes receiving patient information at the data processing device and selecting a subcutaneous insulin treatment for tube-fed patients from a collection of subcutaneous insulin treatments. The selection is based on the blood glucose measurements and the patient information. The subcutaneous insulin treatment program for tube-fed patients determines recommended insulin doses based on the blood glucose times. The method also includes executing, using the data processing device, the selected subcutaneous insulin treatment.

Some embodiments of an infusion pump system can include a controller in which one or more features sets to be provided by the controller are enabled or disabled based upon the particular pump device that is connected to the controller. For example, in some embodiments, one or more advanced features of the controller are available to the user only when a first type of pump device (e.g., having predefined settings stored therein) is connected to the controller, and those advanced features of the controller are disabled when a second type of pump device is connected to the controller.

Described herein are tetherless, forehead-mounted temperature regulation apparatuses configured to enhance sleep.

A system for generating a hypoglycemia risk signal associated with exercise-induced Hypoglycemia. The system can include a processor configured to obtain a blood glucose signal (BG.sub.start), a ratio of absolute insulin on board over total daily insulin signal (IOB.sub.abs/TDI), and an initial glycemic slope signal (S.sub.0); generate a hypoglycemia risk signal based on a hypoglycemia prediction algorithm that determines the probability of a user being hypoglycemic during or after exercise based on the obtained BG.sub.starts, IOB.sub.abs/TDI and S.sub.0.

The disclosure is concerned with privacy and integrity of personalized protected health information when transmitted to a cloud computing facility and subsequently distributed to a plurality of stakeholders. An electronic unit of a drug delivery device is configured to prepare payload data comprising data items according to an allocation scheme, and to encrypt, based on an encryption key, and transmit data including the payload data. The allocation scheme and the encryption key are defined for each of a plurality of data subscribers. Accordingly, personalized protected health information payload data is suitably protected with generator-to-subscriber or pass-through data security measures, and any intermediary node or data server in the communication network lacking a matching decryption key will not have access to unencrypted payload data.

An electronic tag includes a housing; a processor within the housing; a transceiver configured within the housing and coupled to the processor; a display coupled to the housing and the processor, and configured to display information received via the transceiver; a clamping mechanism coupled to the housing and configured to secure the electronic tag to an intravenous (IV) tubing; and a sensor configured within the housing, and configured to measure a property of a fluid in an IV tubing at a location of the clamping mechanism.

A system and method can provide for a remote electronic device to be used to remotely initiate delivery of a medicament bolus with a medical device, such as an insulin pump, with the medical device providing audible or tactile confirmation of the programmed bolus. The bolus amount can be calculated by or programmed or otherwise entered into the smartphone, etc., and then transmitted to the medical device. When the pump receives the transmitted bolus amount, it issues one or more indications such as audible sounds and/or vibrations in any number of desired combinations. For instance, each individual sound or vibration may correspond to an increment of the medicament. The user can therefore determine the size of the medicament bolus by the number of sounds or vibrations and can confirm or cancel delivery of the bolus.

Methods and system for treating obstructive sleep apnea and snoring are disclosed. The system generally comprises a mask for delivering pressurized air to patient's breathing orifice, a sensing mechanism for continuously assessing the state of patient's breathing and a pressure generator for generating the pressurized air in the mask. The pressurized air is applied to the breathing orifice only during selected portions of the breathing cycle, when such pressure might be required to prevent occlusion of the airway or to restore patency of the airway after such occlusion occurs.

A method of administering insulin includes receiving glucose measurements of a patient at a data processing device from a continuous glucose monitoring system. The glucose measurements are separated by a time interval. The method also includes receiving patient information at the data processing device and selecting a subcutaneous insulin treatment from a collection of subcutaneous insulin treatments. The selection is based on the glucose measurements and the patient information. The selection includes one or more of a subcutaneous standard program, a subcutaneous program without meal boluses, a meal-by-meal subcutaneous program without carbohydrate counting, a meal-by-meal subcutaneous program with carbohydrate counting, and a subcutaneous program for non-diabetic patients. The method also includes executing, using the data processing device, the selected subcutaneous insulin treatment.